Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3

Kneitz, Burkhard; Krebs, Markus; Kalogirou, Charis; Schubert, Maria; Joniau, Steven; van Poppel, Hein; Lerut, Evelyne; Kneitz, Susanne; Scholz, Claus Jürgen; Ströbel, Philipp; Gessler, Manfred; Riedmiller, Hubertus; Spahn, Martin (2014). Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. Cancer research, 74(9), pp. 2591-2603. American Association for Cancer Research AACR 10.1158/0008-5472.CAN-13-1606

[img] Text
Spahn_Can Research_Survival in high-risk pr ca.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB)

A lack of reliably informative biomarkers to distinguish indolent and lethal prostate cancer is one reason this disease is overtreated. miR-221 has been suggested as a biomarker in high-risk prostate cancer, but there is insufficient evidence of its potential utility. Here we report that miR-221 is an independent predictor for cancer-related death, extending and validating earlier findings. By mechanistic investigations we showed that miR-221 regulates cell growth, invasiveness, and apoptosis in prostate cancer at least partially via STAT1/STAT3-mediated activation of the JAK/STAT signaling pathway. miR-221 directly inhibits the expression of SOCS3 and IRF2, two oncogenes that negatively regulate this signaling pathway. miR-221 expression sensitized prostate cancer cells for IFN-γ-mediated growth inhibition. Our findings suggest that miR-221 offers a novel prognostic biomarker and therapeutic target in high-risk prostate cancer.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology

UniBE Contributor:

Spahn, Martin

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0008-5472

Publisher:

American Association for Cancer Research AACR

Language:

English

Submitter:

Katharina Morgenegg

Date Deposited:

26 Feb 2015 17:01

Last Modified:

05 Dec 2022 14:41

Publisher DOI:

10.1158/0008-5472.CAN-13-1606

PubMed ID:

24607843

BORIS DOI:

10.7892/boris.63514

URI:

https://boris.unibe.ch/id/eprint/63514

Actions (login required)

Edit item Edit item
Provide Feedback